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Initiatives to Support Local Pharmaceutical Production 
of Quality Essential Medicines IN EAST AFRICA
INTRODUCTION 
Access to essential medicines is a global campaign. The global community has a milliard of initiatives that reduce the 
negative impact of pandemic diseases and 
support identification of quality sources in 
the value chain. 
The donor community response has 
supported the purchase of generic 
medicines, particularly against HIV/AIDS, 
TB and malaria. Since 2002, an annual 
amount of more than US$4 billion has 
been invested in the purchase of the fixed 
dose combinations in ARV and anti-malarial 
drugs. This has led to a significant drop in 
treatment cost and considerable increase in 
the number of people on treatment.  In sub-
Saharan Africa, there was a 13-fold increase  
from 1% in 2002 (300,000 out of 11 million 
adults) to 37% (5 million from 10.4 million 
eligible for ARV treatment).  
It is important that these gains are not 
only realised, but also have sustainable 
mechanisms to ensure access of quality 
essential medicines via secure source(s) 
for continuous availability of quality 
essential medicines. The risk categorisation 
approach provides a robust evidence-
based, scientifically sound way to manage 
pharmaceutical manufacturers, to ensure 
they attain WHO good manufacturing 
practice (GMP) in their facilities.
The WHO report1 states that one of the 
targets of the Sustainable Development 
Goals (SDGs) and a key factor in achieving 
Universal Healthcare (UHC) is access to 
safe, effective and quality medicines and 
vaccines.  The United Nations Industrial 
Development Organisation (UNIDO) 
has also emphasised that many deaths 
could be prevented if safe and efficacious 
medicines were readily available to treat 
patients, and that inaccessibility would 
be increased by existence of substandard 
and counterfeit products on the market.
At the same time, medicines have a 
business and health interface that evokes 
socio-economic considerations, and 
interests must be carefully actuated. 
However, there is good justification that 
local pharmaceutical producers (LPPs) 
can reduce the disease burden of a 
country and improve the health status 
of its citizens. Local pharmaceutical 
production facilitates industrial and 
economic growth through infrastructure 
development, market access with 
potential for insulation against the 
unpredictable burden of new diseases 
and epidemics (e.g. Ebola) that may 
require unprecedented solutions. 
LPPs provide:  
a) Secure source of quality medicines 
and supplicants to substandard and 
counterfeits. 
b) Prevention of discontinued supplies or 
stock outs. 
c) Promotion of local value chain. 
d) Creation of jobs and technology 
transfer. 
e) Provision of service to the advancing 
Global and national initiatives have 
worked concurrently to support 
and sustain local pharmaceutical 
production (LPP) to ensure access 
to quality essential medicines. 
Categorisation of the LPP is a key 
catalyst for growth of the sector in 
terms of product range, security 
of the medicines, access and 
availability of quality essential 
medicines.
A stimulus scheme to support 
and sustain LPP must adhere to 
conformance to international 
standards of products, processes, 
facilities and regulatory function, 
in a manner that guarantees the 
value chain. The scheme must also 
be a foundation for innovation, 
research and development, 
human resource development and 
attract investment in the sector. 
The scheme should inform the 
levels of quality performance and 
risk categorisation.
1Addressing the global shortage of, and access to, medicines 
and vaccines January 2018, Report by the Director-General.
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practical implications. For instance, 
GMP improvements – a requirement 
for supply of medicines – is an 
expensive exercise. In most cases, 
access to financing hampers GMP 
improvements, emanating from the 
above-mentioned support programs. 
As such, there is need to rethink on 
how governments could support LPPs 
in order for them to attain GMP and 
in return contribute towards access to 
affordable medicines at the right time. 
Additionally, companies that have 
invested heavily to be GMP compliant  
as per the regulatory requirements 
feel that a level-playing field lacking 
due to the cost of compliance, 
which  makes them less competitive 
than non-compliant companies. 
For this reason, companies tend to 
avoid investing heavily in product 
development because of the 
regulatory gap. This concern has 
previously been raised with regulators 
by the stakeholders4.  To address this 
issue, there is need for a pragmatic 
industry-accepted approach. 
UNIDO recently published a report5 
highlighting how local pharmaceutical 
production could be boosted. It 
highlights that the future for LPP 
non-communicable diseases, and 
offers a sustainable source beyond 
donor programmes. 
Several initiatives have been rolled 
out to help boost pharmaceutical 
manufacturing in Africa. They include 
efforts by WHO on TRIPS flexibilities, 
UNIDO’s global project support 
programmes for the manufacturing 
sector to attain WHO GMP standards, 
and Health Action Internationals 
(HAI) pharma commercial viability/
improvement studies. They are 
geared towards strengthening 
local pharma production through 
quality improvement interventions, 
price preference, and policy shift 
amongst others. Furthermore, 
regulatory policies to support local 
manufacturing in Africa such as 
AMRH2,3, have also been developed. 
They are aimed at promoting the 
regulation of medicines in Africa and 
sharing experiences, technical know-
how and capacity building especially in 
the pharma sector.
However, these efforts have not 
translated to the growth of the sector 
as anticipated. This is not surprising 
though, because there is a disconnect 
between policy development and the 
• More than 2 billion people worldwide cannot get the 
medicines they need.
• LPPs can help vulnerable populations, especially those 
in remote areas, to access quality medicines, thus 
contributing to ‘’leaving no one behind, and reaching 
the furthest behind first’’, the overarching principle of 
2030 agenda for sustainable development.
• LPPs can reduce the dependency on international 
donations and shrinking number of overseas 
companies who dominate the global market.
• LPPs are easier to monitor and control, and can help 
curb the vast influx of sub-standard medicines into 
developing counties.
• While LPPs are widespread, most companies operate 
below international standards. Helping to upgrade 
their production contributes directly to people’s 
health, as well as to inclusive and sustainable industrial 
development (ISID). 
Source: UNIDO Pharmaceutical Production in Developing Countries
2WHO Drug Information Vol. 28 No. 1, 2014.
3AMRH Newsletter 1Q 2019
4Discussions with CEOs from the pharma companies
5UNIDO Report on Boosting Pharmaceutical Production
growth will rely heavily on national 
governments and collaboration with 
global and regional agencies. The 
report articulates the need to ensure 
adherence to international standards, 
GMP roadmaps, GMP assessments 
and attainment of WHO-GMP. 
It also highlights the need for capacity 
building and more importantly, the 
need for governments to set policies 
to harness opportunities within the 
health budget. This will help to prop 
up local manufacturing, subject to 
quality and regulatory requirements. 
For instance, it shows that with 
regards to quality medicines, ensuring 
access to affordable financing is a key 
component to the success of LPP. 
To this end, there is an opportunity to 
develop a quality GMP-linked incentive 
mechanism, to not only boost access 
to affordable medicines, but to ensure 
that the industry also aspires to attain 
highest possible quality standards.
In the just concluded study, 
commissioned by ACTS, - 
Pharmaceutical Partnerships for 
Increased Access to Quality Essential 
Medicines in the East Africa Region 
– one of the key objectives was to 
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identify policies and regulations that 
impact innovation and development 
of new products in the local 
pharmaceutical industry. 
There was also need to propose 
mitigation strategies to reduce the 
product gap between the national 
essential medicines lists and 
medicines that are manufactured. 
Linked to this, was to make policy 
proposals that could be used to 
incentivise the local manufacturers to 
invest in quality improvements and 
respond to the national health needs.
APPROACHES AND RESULTS
A survey was conducted to determine 
the production competence level 
of LPPs, existing collaborations and 
pharma sector policy work in EAC. 
Information was obtained from the 
pharmaceutical industry, institutions 
of research, academia and policy 
makers in the Ministry of Health/
Ministry of Trade and Industry. Sixteen 
LPPs from Kenya participated in the 
study. 
Summary of the key findings from the 
study
1. Range of products manufactured 
by the local industry
The local industry does not 
manufacture all the products listed as 
essential medicines predominantly the 
non-sterile products, solids (tablets, 
capsules), liquids (syrups, suspensions) 
and semi-solids (ointments, creams). 
• Only 28% of the listed essential 
medicines are produced. 
• About 56% of these products 
are solids and 63% are 
for management of non-
communicable diseases. 
• There were about three 
manufacturers of sterile products 
at the time of the study.
• The production capacity in this 
industry is underutilised. The 
average production capacity 
utilisation of local pharmaceutical 
producers (LPP) in Kenya (2-Shift 
basis) is ~43% (tablets, 48%, 
capsules, 28% and liquids, 52%). 
• There is adequate skills-mix  for 
the current levels of production of 
essential medicines. 
• Many manufacturers are 
upgrading their facilities to comply 
with local and international GMP 
standards, and it is a capital-
intensive process. 
2. Policies and regulations impacting 
innovation and development of 
new products
Policies and regulations within the 
government must work in a coherent 
manner with a clear roadmap to 
develop the LPP. They must ensure 
that the value chain maintains quality 
and supports improvements. Some of 
the constrains include:
• Lack of clear and pragmatic 
government policy to support 
LPP leading to apprehensive 
behaviour when it comes to 
investing in their factories. 
• Inadequate incentives on 
pharmaceutical inputs including 
the 15% public procurement. 
• Lack of pragmatic strategies for 
product development in the 
industry, which has resulted into 
common ‘me too’ products. 
3. Collaborations and  partnerships 
in pharmaceutical manufacturing 
All multi-national corporations’  
growth in terms of market, products 
and strength in research, development 
and innovations is a result of  
value-adding collaborations and 
partnerships with other institutions.
• This is uncommon, though it has 
been acknowledged as important 
towards enhancing  GMP 
compliance, market penetration 
and improvement of product 
portfolio. These partnerships 
involve technical transfers. 
Examples include Universal 
Corporation Limited/Strides-
Shasun Merger, Quality Chemicals 
/CIPLA Quality, and an intended 
PPP between Dawa Group, 
Merck and Government of Kenya 
geared towards the production of 
vaccines. 
• In addition, there is lack of clear 
guidelines and/or awareness on 
technology transfer, collaborations 
and partnerships. 
• Current training curricula and 
research priorities by local 
universities and research 
institutions are also not 
necessarily aligned to the 
technical needs of the dynamic 
industry needs, e.g. technological 
advancements.
IMPLICATIONS AND  
RECOMMENDATIONS
Based on the study, it was clear that 
there is need to review and improve 
on the exisitng  pharmaceutical 
industry’s relevant policies so as to 
make them practical and tenable.
They include: 
(i) Developing  a tangible framework 
for  investment in the pharmaceutical 
sector and auxilliary industry; 
(ii) Establishing a framework for 
attainment of stringent regulator 
status of the National Medicine 
Regulatory Authority (NMRA) for 
international recognition  and 
benchmarking GMP compliance of 
companies; 
(iii) Developing a harmonised incentive 
regime to catalyse growth and 
expansion of LPPs (expounded below)
The latter is the basis for the policy 
incentive mechanism proposed below.
Quality ranking and risk 
categorisation of LPP proposal
The categorisation plan developed by 
UNIDO6 in the Kenya GMP roadmap 
is a good starting point to ensure that 
GMP is adhered to while at the same 
time, support companies to make 
incremental GMP improvents. This 
provides a way of determining the risk 
inherent in consistently manufacturing 
quality products such that a site with 
sufficient infrastructure and quality 
systems is rated as low risk and most 
likely to produce quality products and 
vice versa.
While the  GMP roadmap 
categorisation into A; B; C was 
meant for determining the root 
cause of inferior quality, fixing 
6The consultant in this ACTs project was the author of 
the UNIDO report. Companies are ranked based on their 
GMP/quality positions. Categorisation model has three 
classes, i.e. A, B and C, the latter being the lowest in 
quality.
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quality problems, and even for GMP 
inspector/regulator to use for licensing 
of premises and products, it can be 
enriched by turning it into an incentive 
vehicle to provide a win-win situation 
for the parties. 
One of the fundamental ideals 
in quality ranking (QR) and risk 
categorisation is to ensure a level 
playing field for all manufacturers 
within the manufacturing 
environment, that comply with GMP 
requirements for site and quality 
management systems (QMS) (Exhibit 
1). This, admittedly, would reduce the 
risk of entry of poor quality products 
to the distribution chain. Based on the 
results of the study, there is need to 
have an incentive approach for LPPs. 
Exhibit 1 illustrates a potential quality-
based incentive vehicle for LPPs. It 
is a risk-based categorisation model 
that has three classes; class A, B 
and C in terms of GMP compliance, 
derived and based on site and QMS 
related GMP requirements. The 
licensing for manufacture would take 
into consideration the suitability of 
a facility to manufacture specific 
products.  Highrisk facilities will 
manufacture low risk products, 
for example, disinfectants and 
increasingly adopt other products.
The categorisation model will 
empower the national medicines 
regulatory authorities in EAC to be 
the means of industrial growth, 
and to stimulate the attainment of 
international standards. It is a strategy 
to ensure compliance to international 
standards by all facilities via a stepwise 
approach for all manufacturers to 
attain the WHO GMP standards within 
a given period. It provides a growth 
pattern with the niche to achieve 
higher status of quality and a means of 
regulator enforcement. 
The industry, on its own, should 
develop a quality culture with 
growth patterns and alignment to 
health priorities that take cognisance 
of the SDG No. 3 and access to 
essential medicines. In a way, it will 
realign the industry into categories 
that will stimulate upward growth, 
quality upgrades and investment to 
increase the product range within 
the essential medicines list and other 
Exhibit 1: Categorisation and Benefits     Source: author adapted from Kenya GMP Roadmap
formulations. At the same time, 
LPPs will feel empowered because 
their improvements will be linked to 
potential increase in supply portfolios 
and competitiveness. 
Implementation can be achieved 
by carrying out a baseline quality 
assessment of all or selected 
manufacturers by GMP inspectors. 
Upon the findings, facility-based CAPA  
will be developed and a project map 
agreed upon between the regulatory 
agency and the manufacturer, with 
clear timelines and milestones. 
There will be a periodic review on 
the progress but more importantly, a 
qualification assessment to determine 
the quality status of both site and 
quality management systems as the 
criterion for categorisation. A scenario 
will be set where good performance 
will raise their quality status to full 
compliance, and likewise prevent 
a fall back to lower quality through 
regulatory controls that will be 
applicable. 
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Exhibit 2: Risk categorisation model stakeholders and their functions
Exhibit 3: Risk Categorisation model for Sustainable LPP of high-quality medicines
POLICY FOCUS FUNCTIONS
Access to essential medicines This a right which must be exercised by governments and public procurement agencies 
using the essential Medicines List but unlimited access in private sector  
Medicines security To ensure that all items on the EML are available and source is known for urgent and 
emergency supplies
Disease burden and morbidity Focus on treatment regimens and ensure continuous availability of quality medicines 
from GMP certified and ‘qualified’ suppliers. Restriction of unlisted manufacturers to the 
market 
Incentives to LPP To be graduated and linked to quality improvements since the high-risk manufacturers 
with least investment in quality improvement. It provides a stimulus for quality improve-
ment
Valuation of procurement 
tenders 
Price valuation in identify and match import country export incentives and domestic lev-
ies, tariffs and non-tariff fees (if any) to off-set overheads for genuine price comparison 
Quality ranking & Risk 
categorisation
To stimulate quality improvements and give assurance of quality products in the distribu-
tion chain thus expanding market for compliant products
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CONCLUSION
This risk categorisation is a suitable 
tool for benchmarking GMP 
compliance of companies and can also 
be used to monitor the companies’ 
development towards full WHO GMP 
compliance.
Suffice it to state that, enforcement 
agencies can use their mandate to 
drive upgrades in domestic facilities 
by enforcing corrective actions and 
preventive actions (CAPAs) and follow-
up on implementation and review the 
GMP compliance levels. 
A means of structured incentive 
can be used for different levels of 
categorisation to drive compliance. 
Additionally, a medicines security 
scheme, especially medicines in 
the disease burden regime, and 
determination of local capacity from 
reliable LPP can be derived from low 
risk manufacturers in category A and 
B. Risk categorisation is therefore 
a stimulus scheme that promotes 
industrial growth and rewards quality 
improvements, and assures access to 
quality essential medicines.
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